Abstract
The new chemical entity (NCE) has been knocked as novel antidiabetic agent, e.g. Saroglitazar. Saroglitazar is a drug for the treatment of Type II diabetes. Saroglitazar is marketed under the trade name Lipaglyn, developed by the Zydus Cadila. Lipaglyn is the first indigenously developed NCE by any Indian pharmaceutical company, ever. Lipaglyn has been approved for the treatment of Type II diabetes by the Drug Controller General of India in June 2013. Lipaglyn is indicated for the patients suffering from diabetes dyslipidemia. It also provides the option of a once-daily oral therapy. Saroglitazar regulates the lipid parameters as well as glycemic control. The present article describes Saroglitazar with its chemical synthesis and patent status with its summary of clinical studies.
Keywords: Cadila, lipaglyn, saroglitazar, diabetes, PPAR agonist, NCE, approval.
Current Drug Targets
Title:The First Approved Agent in the Glitazar’s Class: Saroglitazar
Volume: 15 Issue: 2
Author(s): Ritesh Agrawal
Affiliation:
Keywords: Cadila, lipaglyn, saroglitazar, diabetes, PPAR agonist, NCE, approval.
Abstract: The new chemical entity (NCE) has been knocked as novel antidiabetic agent, e.g. Saroglitazar. Saroglitazar is a drug for the treatment of Type II diabetes. Saroglitazar is marketed under the trade name Lipaglyn, developed by the Zydus Cadila. Lipaglyn is the first indigenously developed NCE by any Indian pharmaceutical company, ever. Lipaglyn has been approved for the treatment of Type II diabetes by the Drug Controller General of India in June 2013. Lipaglyn is indicated for the patients suffering from diabetes dyslipidemia. It also provides the option of a once-daily oral therapy. Saroglitazar regulates the lipid parameters as well as glycemic control. The present article describes Saroglitazar with its chemical synthesis and patent status with its summary of clinical studies.
Export Options
About this article
Cite this article as:
Agrawal Ritesh, The First Approved Agent in the Glitazar’s Class: Saroglitazar, Current Drug Targets 2014; 15 (2) . https://dx.doi.org/10.2174/13894501113149990199
DOI https://dx.doi.org/10.2174/13894501113149990199 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Genetic and Molecular Basis of QTL of Diabetes in Mouse: Genes and Polymorphisms
Current Genomics Is it Worth CANVASing for CREDENCE? A Benefit-risk Analysis
Current Diabetes Reviews MR Imaging of Pancreatic Islets: Tracking Isolation, Transplantation and Function
Current Pharmaceutical Design Psychosocial Factors and Diabetes Mellitus: Evidence-Based Treatment Guidelines
Current Diabetes Reviews Management of Type-1 and Type-2 Diabetes by Insulin Injections in Diabetology Clinics - A Scientific Research Review
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Changes in Serum Nampt Levels and Its Significances in Diabetic Nephropathy Patients-The Potential Role of Nampt in T2DM with Diabetic Nephropathy
Endocrine, Metabolic & Immune Disorders - Drug Targets Physical Activity, Insulin Action, and Diabetes Prevention and Control
Current Diabetes Reviews A Critical Review of Atypical Antipsychotic Utilization: Comparing Monotherapy with Polypharmacy and Augmentation
Current Medicinal Chemistry Recommendations for Severe Hypertriglyceridemia Treatment, are there New Strategies?
Current Vascular Pharmacology Managing Hypoglycemia in Diabetes May Be More Fear Management Than Glucose Management: A Practical Guide for Diabetes Care Providers
Current Diabetes Reviews Vitamin D Insufficiency and Diabetes Risks
Current Drug Targets Efficacy and Cardiovascular Safety of DPP-4 Inhibitors
Current Drug Safety Surgical Esophageal Emergencies
Current Respiratory Medicine Reviews The Effects of Psychotropic Drugs on the Regulation of Glucose Metabolism
Current Diabetes Reviews Diabetes Case Identification Methods Applied to Electronic Medical Record Systems: Their Use in HIV-Infected Patients
Current HIV Research Contemporary Roles of the Pediatric Psychologist in Diabetes Care
Current Diabetes Reviews Somatostatin and its Analogs
Current Drug Targets Stem-cell-based Therapies for Improving Islet Transplantation Outcomes in Type 1 Diabetes
Current Diabetes Reviews Side Effects of Atypical Antipsychotic Drugs
Current Pharmaceutical Design The IGF-I Signaling Pathway
Current Pharmaceutical Design